Abbott Laboratories (NY:ABT)

100.61 +3.11 (+3.19%)

Delayed Quote Updated: 2:35 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

58 59 Next >

Jim Carmer Is 'A Seller' Of This Company Because 'Elon Musk Said That He Doesn't Like That Business' ↗

October 11, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Abbott Laboratories (NYSE: ABT) is a "very good company and will be up to the—let’s say—up to the challenge. I think that’s fair.

Via Benzinga

3 Dividend Kings Every Investor Should Own to Survive a Market Crash ↗

October 10, 2023

Dividend stocks that raise their payout beat all other kinds of stocks, making Dividend Kings the best stocks to buy in a downturn.

Via InvestorPlace

Lumentum Lights Up on the AI and ML Surge

October 10, 2023

Optical and photonics manufacturer Lumentum Holdings Inc. (NASDAQ: LITE) provides optical components and lasers to data centers, cloud providers, telecoms

Via MarketBeat

Topics Artificial Intelligence

2 Magnificent Dividend Stocks to Buy Hand Over Fist in October ↗

October 09, 2023

These two healthcare stocks are reliable passive income vehicles.

Via The Motley Fool

Looking Into Abbott Laboratories's Recent Short Interest ↗

October 06, 2023

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $2,900 Today ↗

October 05, 2023

Via Benzinga

Abbott Laboratories Unusual Options Activity ↗

September 28, 2023

Via Benzinga

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

October 01, 2023

These companies are helping change medicine; they could make boatloads of money along the way.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2023

Via Benzinga

Abbott Laboratories And More On CNBC's 'Final Trades' ↗

September 29, 2023

On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Innovator U.S.

Via Benzinga

Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 Years ↗

September 29, 2023

A basket of passive income opportunities in oil and gas, renewable energy, and healthcare.

Via The Motley Fool

Why Abbott Says It Won't Be A Casualty Of The Weight-Loss Battle ↗

September 28, 2023

Abbott and Dexcom stocks have tumbled as GLP-1 drugs have gripped the nation.

Via Investor's Business Daily

Looking At Abbott Laboratories's Recent Unusual Options Activity ↗

September 25, 2023

Via Benzinga

Abbott Stock: Bear vs. Bull ↗

September 23, 2023

Abbott is a favorite of income-oriented investors, but is the price right?

Via The Motley Fool

P/E Ratio Insights for Abbott Laboratories ↗

September 22, 2023

Via Benzinga

2 Stocks to Benefit from the Aging Population

September 26, 2023

The growth of the aging population is entirely predictable, which makes now an ideal time to consider these two health and wellness stocks

Via MarketBeat

Topics Retirement

3 Best Stocks to Buy in September and Hold Forever ↗

September 24, 2023

Healthcare blue chip stocks with proven track records can be excellent long-term investments.

Via The Motley Fool

3 Unstoppable Nasdaq 100 Stocks Just Waiting to Be Bought ↗

September 21, 2023

Tech stocks were the primary fuel for a decades-long bull market, and these three Nasdaq stocks to buy can lead the market forward.

Via InvestorPlace

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗

September 21, 2023

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.

Via Benzinga

This Is What Whales Are Betting On Abbott Laboratories ↗

September 20, 2023

Via Benzinga

(ABT) - Analyzing Abbott Laboratories's Short Interest ↗

September 20, 2023

Via Benzinga

Apple Taps Seasoned Executive To Head 'Secret' Team Developing Glucose Monitoring Device - Stocks To Watch ↗

September 15, 2023

Apple Inc (NASDAQ: AAPL) has appointed Tim Millet, a seasoned executive with a background in iPhone and Mac chip technology, to oversee its secretive team dedicated to developing a noninvasive blood...

Via Benzinga

2 Dividend Kings to Buy on the Dip and Hold Forever ↗

September 15, 2023

Don't ignore these stocks just because the rest of the market is.

Via The Motley Fool

Why Jim Cramer Warns Investors To Avoid This Stock Up Over 90% This Year ↗

September 15, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said UiPath Inc. (NYSE: PATH) is a "decent" stock. Cramer said the company is not making money, and he doesn’t recommend stocks that don’t make money.

Via Benzinga

Could Abbott Laboratories Stock Help You Become a Millionaire? ↗

September 15, 2023

One promising area of its business is diabetes care, which experienced significant growth this year.

Via The Motley Fool

If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today ↗

September 14, 2023

Via Benzinga

Is Abbott Laboratories a Buy? ↗

September 12, 2023

If you're willing to invest with the right mindset, it could be a great option.

Via The Motley Fool

Less Is More: Abbott’s Approach to Packaging Innovation

September 11, 2023

Via ACCESSWIRE

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 11, 2023

Via Benzinga

3 No-Brainer Dividend Stocks to Buy No Matter What the Market Is Doing ↗

September 09, 2023

You'll want to hold on to these players for the long term.

Via The Motley Fool

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.